

## 8<sup>th</sup> European Clinical Microbiology and Immunology Congress &

## 3<sup>rd</sup> World congress on Biotechnology

June 12-13, 2019 | Edinburgh, Scotland



## Irina Zavestovskaya<sup>2</sup>, Shawn Murphy<sup>3</sup>, Hiroyuki Abe<sup>4, 5</sup>, John Mendelsohn<sup>5</sup> and William Thilly<sup>6</sup>



<sup>1</sup>Sechenov University, Russia <sup>2</sup>Moscow Engineering Physical Institute (MEPhI), Russia <sup>3</sup>Autoimmunity Research Foundation, USA <sup>4</sup>ISPM, Tokyo, Japan <sup>5</sup>Harvard Medical School, USA <sup>6</sup>Massachusetts Institute of Technology, USA

Personalized and precision medicine as a unique healthcare model through the view of biodesign and translational armamentarium of the newest generation

A new systems approach to diseased states and wellness result in a new branch in the healthcare services, namely, personalized and precision medicine (PPM). To achieve the implementation of PM concept, it is necessary to create a fundamentally new strategy based upon the subclinical recognition of biopredictors of hidden abnormalities long before the disease clinically manifests itself.

Each decision-maker values the impact of their decision to use PPM on their own budget and well-being, which may not necessarily be optimal for society as a whole. It would be extremely useful to integrate data harvesting from different databanks for applications such as prediction and personalization of further treatment to thus provide more tailored measures for the patients resulting in improved patient outcomes, reduced adverse events and more cost-effective use of health care resources. A lack of medical guidelines has been identified by the majority of re-sponders as the predominant barrier for adoption, indicating a need for the development of best practices and guidelines to support the implementation of PPM.

Implementation of PPM requires a lot before the current model "physician-patient" could be gradually displaced by a new model "medical advisor-healthy person-at-risk". This

is the reason for developing global scientific, clinical, social and educational projects in the area of PPM to elicit the content of the new branch.

## **Speaker Biography**

Sergey Suchkoy graduated from Astrakhan State Medical University and awarded with MD, then in 1985 maintained his PhD at the I M Sechenov Moscow Medical Academy and in 2001, maintained his doctorship degree at the Nat Inst of Immunology, Russia. From 1987 through 1989, he was a senior researcher at Koltzov Inst of Developmental Biology. From 1989 through 1995, he was a head of the lab of clinical immunology, Helmholtz Eye Research Institute in Moscow. From 1995 through 2004, as a chair of the dept for clinical immunology, Moscow Clinical Research Institute (MONIKI). He has been trained at NIH; Wills Eye Hospital, PA, USA; Univ of Florida in Gainesville; UCSF, S-F, CA, USA; Johns Hopkins University, Baltimore, MD, USA. He was an executive secretary-in-chief of the editorial board, biomedical science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, he is a chair, dept for personalized and translational medicine, I M Sechenov First Moscow State Medical University. He is a member of the: New York Academy of Sciences, USA; American Chemical Society (ACS), USA; American Heart Association (AHA), USA; EPMA (European Association for Predictive, Preventive and Personalized Medicine), Brussels, EU; ARVO (American Association for Research in Vision and Ophthalmology); ISER (International Society for Eye Research) and PMC (Personalized Medicine Coalition), Washington, USA.

e: ssuchkov57@gmail.com

